GICS Sector : Healthcare
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide.The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM).It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.
In the fourth quarter of 2025, Apyx Medical reported record revenue of $19.2 million, up 35% YoY, driven primarily by a 38% jump in its Surgical Aesthetics segment to $16.7 million. Gross margin guidance for 2026 is conservative, reflecting a shift toward higher‑margin AYON sales and a lighter OEM mix. The company posted an EPS of –$0.03 versus an analyst estimate of –$0.06, signaling improving profitability despite lingering negative earnings (Goodwin, Q4 2025 earnings call).
Publication Date: Apr -17
The AYON body‑contouring system, introduced six months ago, accounted for roughly 80% of the quarter’s surgical sales, with the remaining 20% coming from new customers adopting the Renuvion platform. Sales momentum has exceeded expectations across every metric, and the company is poised to receive power‑liposuction clearance in mid‑2026, further cementing AYON’s position as the first fully integrated system.
Management highlighted that lower OEM margins will be offset by higher margins from the Surgical Aesthetics segment and a favorable geographic mix, notably stronger sales in China. The guidance for gross margin remains conservative, yet the company expects a modest improvement as the product mix continues to tilt toward AYON.
Apyx projects cash‑flow positivity by Q4 2026 and anticipates sustained positive cash flow through 2027. The upcoming release of a power‑assisted handpiece in the first half of 2026, along with planned regulatory approvals in Europe, Brazil, and Colombia, should accelerate international adoption and sustain revenue growth.
With a P/E ratio of –14.82 and a P/S ratio of 3.12, Apyx trades at a discount to peers, reflecting the market’s adjustment for current negative earnings. The negative EV/EBITDA of –35.38 further underscores the valuation pressure, while the company’s P/B ratio of 11.43 indicates ample book value relative to market price.
Investors should weigh the upside potential of AYON’s market dominance against risks such as regulatory delays and the competitive landscape. The firm’s early‑stage growth in a market driven by GLP‑1 drug adoption offers a compelling narrative, but the negative earnings profile and high valuation multiples warrant cautious scrutiny.
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Apr -01
Apyx Medical Corporation (APYX) Q4 2025 Earnings Call Transcript
Mar -10
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Mar -10
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
Feb -18
Chuck Royce's Recent Transaction with Apyx Medical Corp: An In-Depth Analysis
Jan -24
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Jan -12
Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
Dec -03
Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
Nov -18
Apyx Medical Corporation's Advanced Energy segment growth is driven by increasing adoption of minimally invasive procedures, rising demand for electrosurgical devices, and expanding applications in laparoscopic and endoscopic surgeries. Additionally, strategic partnerships, product innovations, and geographic expansion contribute to the 12% growth rate.
Apyx Medical Corporation's 14% growth in Original Equipment Manufacturing is driven by increasing demand for electrosurgical devices, expansion into new markets, and strategic partnerships. Additionally, advancements in technology, such as the development of innovative products like the Renuvion system, have contributed to the company's growth.
Apyx Medical's Renuvion is a helium plasma technology used for precision cutting, coagulation, and ablation of soft tissue in medical procedures.
Apyx Medical's J-Plasma is a helium plasma technology used for precise dissection, coagulation, and ablation of soft tissue in surgical procedures.
Apyx Medical's Renuvion Dermal Handpiece is a helium plasma technology used for skin resurfacing and rejuvenation.
Apyx Medical's Renuvion APS is an advanced plasma system used for precision cutting, coagulation, and ablation of soft tissue in medical procedures.
Apyx Medical Corporation operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the medical device industry.
Apyx Medical Corporation's customers are primarily hospitals and medical facilities, which have limited bargaining power due to the specialized nature of the company's products.
Apyx Medical Corporation relies on a few key suppliers for critical components, which gives them some bargaining power, but the company's strong relationships and diversified supply chain mitigate this risk.
The medical device industry has high barriers to entry, including regulatory hurdles and significant capital requirements, which limits the threat of new entrants.
Apyx Medical Corporation operates in a competitive market with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 55.69% |
| Debt Cost | 7.27% |
| Equity Weight | 44.31% |
| Equity Cost | 9.42% |
| WACC | 8.22% |
| Leverage | 125.66% |
Value: 8.4
Growth: 6.4
Quality: 5.2
Yield: 0.0
Momentum: 5.0
Volatility: 3.3
1-Year Total Return ->
Value: 6.9
Growth: 7.4
Quality: 3.3
Yield: 0.0
Momentum: 7.5
Volatility: 0.7
1-Year Total Return ->
Value: 6.6
Growth: 2.9
Quality: 3.9
Yield: 0.0
Momentum: 10.0
Volatility: 0.7
1-Year Total Return ->
Value: 7.8
Growth: 4.7
Quality: 3.9
Yield: 0.0
Momentum: 2.0
Volatility: 1.3
1-Year Total Return ->
Value: 8.7
Growth: 3.3
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 2.0
1-Year Total Return ->
Value: 10.0
Growth: 1.6
Quality: 5.0
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->